A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Inclusion Criteria: Provision of signed and dated, written informed consent prior to any study specific procedures. Healthy male and female participants (of non-childbearing potential) aged 18 to 60 years, inclusive, with suitable veins for cannulation or repeated venipuncture. Females must have a negative pregnancy test at screening and must not be lactating Participants with BMI between 18 and 30 kg/m^2, inclusive, and weighing between 50 kg and 100 kg, inclusive Exclusion Criteria: History or presence of gastrointestinal, hepatic or renal disease, or any other clinically significant disease or disorder Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, or HIV. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first vaccination within 30 days prior to randomization and second vaccination within 10 days of screening Confirmed Coronavirus disease 2019 (COVID-19) infection at admission, by Polymerase chain reaction (PCR) test Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening History or presence of severe allergy/hypersensitivity Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening Positive screen for drugs of abuse, alcohol, or cotinine at screening Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of the study drug Any clinically significant abnormalities in clinical chemistry, hematology, coagulation, urinalysis results, ECG or vital signs